Ergot alkaloids: Nursing pharmacology

Last updated: January 26, 2022

Ergot alkaloids: Nursing pharmacology

Watch later

Watch later

Antibiotics - Glycopeptides: Nursing pharmacology
Corticosteroids - Inhaled: Nursing pharmacology
Oxygen therapy: Nursing pharmacology
Blood products: Nursing pharmacology
Bronchodilators: Nursing pharmacology
Analgesics: Nursing pharmacology
Antihistamines: Nursing pharmacology
Therapeutic communication: Nursing
Diabetes mellitus (DM): Nursing process (ADPIE)
Diabetic ketoacidosis (DKA): Nursing process (ADPIE)
Immunoglobulins: Nursing pharmacology
Physiologic changes - Postpartum: Nursing
Assessment - Postpartum: Nursing
Cesarean birth: Nursing
Postpartum infections: Nursing
Assessment of gestational age: Nursing
Nutrition - Newborn: Nursing
Newborn adaptation to extrauterine life: Nursing
Hemolytic disease of the fetus and newborn: Nursing
Physical assessment - Neonate: Nursing
Group B streptococcus (GBS) infection in pregnancy: Nursing
Neonatal eye prophylaxis: Nursing pharmacology
Streptococcus agalactiae (Group B Strep)
Hyperbilirubinemia: Nursing process (ADPIE)
Large for gestational age (LGA) infant: Nursing
Hepatitis B virus (HBV) infection in pregnancy: Nursing
Brachial plexus injury: Nursing
Postpartum hemorrhage: Nursing
Psychosocial changes - Postpartum: Nursing
Oxytocin: Nursing pharmacology
Rho(D) immune globulin: Nursing pharmacology
Perinatal depression: Nursing
Shoulder dystocia: Nursing
Venous thromboembolism (VTE): Nursing process (ADPIE)
Shock - Hypovolemic: Nursing
Eye conditions: Inflammation, infections and trauma: Pathology review
Otitis media: Nursing
Ventricular septal defect
Disseminated intravascular coagulation (DIC): Nursing
Antepartum assessment - Fetus: Nursing
Common discomforts of pregnancy: Nursing
Ectopic pregnancy: Nursing
Fetal circulation: Nursing
Fetal development: Nursing
Gestational trophoblastic disease: Nursing
Hyperemesis gravidarum: Nursing
Multiple gestation: Nursing
Physiologic changes - Pregnancy: Nursing
Pregestational conditions: Nursing
Psychosocial changes - Pregnancy: Nursing
Spontaneous abortion: Nursing
Placenta previa: Nursing process (ADPIE)
Placental abruption: Nursing process (ADPIE)
Ergot alkaloids: Nursing pharmacology
Prostaglandins: Nursing pharmacology
Analgesics for obstetrics: Nursing pharmacology
Tocolytics: Nursing pharmacology
Prenatal care: Nursing
Preeclampsia and eclampsia: Nursing
Neonatal abstinence syndrome: Nursing
Sudden infant death syndrome (SIDS): Nursing
ADHD: Information for patients and families (The Primary School)
Stimulant medications for attention-deficit hyperactivity disorder (ADHD): Nursing pharmacology
Cerebral palsy: Nursing
Failure to thrive (FTT): Nursing
Pelvic inflammatory disease (PID): Nursing process (ADPIE)
Contraception - Barrier methods: Nursing
Syphilis: Nursing
Chlamydia trachomatis
Candidiasis: Nursing process (ADPIE)
Treponema pallidum (Syphilis)
Gonorrhea and chlamydia: Nursing process (ADPIE)
Genital warts: Nursing
Contraception - Hormonal methods: Nursing
Dementia: Nursing
Alzheimer disease
Antiepileptics: Nursing pharmacology
Dyslipidemias: Pathology review
Schizophrenia: Nursing
Bipolar and related disorders
Mood stabilizers: Nursing pharmacology
Erectile dysfunction
Obsessive-compulsive disorder (OCD): Nursing
Benign prostatic hyperplasia (BPH): Nursing process (ADPIE)
Renal and urinary calculi: Nursing
Antipsychotics: Nursing pharmacology
Physical assessment - Mental status: Nursing
Delirium: Nursing
Restraints
Cataracts: Nursing
Glaucoma: Nursing process (ADPIE)
Peripheral arterial disease (PAD): Nursing process (ADPIE)
Physical assessment - Peripheral vascular system: Nursing
Peripheral venous disease (PVD): Nursing process (ADPIE)
Amputation: Nursing
Treatment for Helicobacter pylori: Nursing pharmacology
Macular degeneration: Nursing
Eye conditions: Retinal disorders: Pathology review
Antidepressants - SSRIs and SNRIs: Nursing pharmacology
Antidepressants - Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs): Nursing pharmacology
Anxiolytics and sedative-hypnotics: Nursing pharmacology
Thrombosis syndromes (hypercoagulability): Pathology review
Pulmonary embolism
Heart failure
Heart failure: Pathology review
Left-sided heart failure: Nursing process (ADPIE)
Coronary artery disease (CAD) and angina pectoris: Nursing process (ADPIE)
Nephrotic syndrome: Nursing
Immune response - Adaptive: Nursing
Inflammatory process: Nursing
Inflammation
Tuberculosis (TB): Nursing
Leukemia: Nursing process (ADPIE)
Breast cancer: Nursing process (ADPIE)
Lung cancer: Nursing
Biology of cancer: Nursing
Skin cancer - Basal cell carcinoma, squamous cell carcinoma, and melanoma: Nursing
HIV (AIDS)
Hypersensitivity reactions - Type I: Nursing
Hypersensitivity reactions - Type III: Nursing
Hypersensitivity reactions - Type II: Nursing
Hypersensitivity reactions - Type IV: Nursing
Physical assessment - Neurological system: Nursing
Antihyperlipidemics - Miscellaneous: Nursing pharmacology
Stroke: Nursing process (ADPIE)
Shock - Septic: Nursing
Shock - Neurogenic: Nursing
Burn injury: Nursing
Thermoregulation : Nursing
Arrhythmias - Atrial flutter (Aflutter): Nursing
Arrhythmias - Atrial fibrillation (Afib): Nursing
Arrhythmias - Supraventricular tachycardia (SVT): Nursing
Arrhythmias - Ventricular tachycardia (Vtach): Nursing
Arrhythmias - Ventricular fibrillation (Vfib): Nursing
Arrhythmias - Premature atrial contractions (PACs): Nursing
Arrhythmias - Premature ventricular contractions (PVCs): Nursing
Arrhythmias - Asystole: Nursing
Arrhythmias - Sinus tachycardia and sinus bradycardia: Nursing
ECG rate and rhythm
Cardiomyopathy: Nursing
Shock - Cardiogenic: Nursing
Endocarditis: Nursing
Cardiac preload
Acute respiratory distress syndrome (ARDS): Nursing
Neonatal respiratory distress syndrome (NRDS): Nursing
Chronic kidney disease (CKD): Nursing
Acute kidney injury (AKI): Nursing process (ADPIE)
Dialysis care: Nursing
Aortic aneurysm: Nursing process (ADPIE)

Notes

ERGOT ALKALOIDS
DRUG NAME
methylergonovine (Methergine)
CLASS
Ergot derivative, oxytocic
MECHANISM OF ACTION
Acts primarily on alpha-adrenergic receptors on uterine and vascular smooth muscle, increasing uterine tone and causing vasoconstriction
INDICATIONS
Postpartum hemorrhage, uterine atony / subinvolution
ROUTE(S) OF ADMINISTRATION
  • IM
  • IV
  • PO
SIDE EFFECTS
  • Uterine hyperstimulation
  • Cardiovascular effects (IV): hypo- or hypertension, Raynaud phenomenon, palpitations, angina, arrhythmias
  • Nausea, vomiting, abdominal pain, diarrhea
  • Allergic reactions: skin rash or swelling of the face, lips, or tongue; or present with headaches, dizziness, vertigo, and tinnitus
  • Ergot toxicity: nausea, vomiting, dyspnea; vascular spasm, limb hypoperfusion, seizures, hallucinations, coma
CONTRAINDICATIONS AND CAUTIONS
  • Pregnancy
  • Hypertension
  • Cardiovascular disease
  • Avoid in clients receiving alpha- or beta-agonists, triptans, azole antifungals, protease inhibitors, and some macrolide antibiotics
  • Use with caution in clients with hepatic or renal disease
ERGOT ALKALOIDS: NURSING CONSIDERATIONS
PREFERRED ROUTE OF ADMINISTRATION
  • IM administration is preferred
  • IV administration is used only in life-threatening situations
ASSESSMENTS
  • Side effects: e.g., hypertension, headache, chest pain, uterine hyperstimulation
  • Possible ergot toxicity: e.g., nausea, vomiting, tinnitus, dyspnea, numbness, tingling and painful extremities
  • Therapeutic response: control of hemorrhage, increased uterine tone
MONITORING
  • Blood pressure, heart rate
  • Uterine tone
  • Vaginal bleeding
CLIENT EDUCATION
  • It is safe to breastfeed after receiving this medication
  • Report nausea, severe abdominal pain, numbness or tingling of extremities, or increased bleeding
Author: Lisa Miklush PhD, RN, CNS
Illustrator: Robyn Hughes, MScBMC

Transcript

Watch video only

Ergot alkaloids are a group of medications produced by the fungus Claviceps purpurea. Ergot alkaloids, or simply ergots, include methylergonovine, which can be used to prevent or treat postpartum hemorrhage.

Other ergots include ergotamine, which can be used to treat severe migraines, as well as bromocriptine, which can be used to treat Parkinson disease.

Now, ergot alkaloids have similar structure to the neurotransmitters norepinephrine, serotonin, and dopamine. As a result, they can act as antagonists on alpha-adrenergic receptors on smooth muscle cells, as well as agonists of serotonin and dopamine receptors, mainly found in the brain.

In particular, methylergonovine primarily acts on alpha-adrenergic receptors on the uterus, increasing the tone, and rate of uterine rhythmic contractions, as well as inducing vasoconstriction.

For this reason, methylergonovine can be administered intramuscularly, and less frequently orally or intravenously, usually after delivery of the placenta to decrease bleeding, and promote uterine involution.

Typically, methylergonovine is used as second-line after safer medications like oxytocin have failed to control the bleeding. However, methylergonovine may cause significant side effects.

The most common ones include gastrointestinal symptoms like nausea or vomiting, as well as abdominal pain and diarrhea. Another important side effect is related to uterine hyperstimulation, where there’s too much contraction, and may result in uterine tetany.

Some clients may develop allergic reactions, such as a skin rash or swelling of the face, lips, or tongue; or present with headaches, dizziness, vertigo, and tinnitus.

Cardiovascular effects are mainly associated with intravenous administration, and include hypo- or hypertension, Raynaud phenomenon, palpitations, angina, and arrhythmias.

Ergot toxicity may cause ergotism, which mainly presents with nausea, vomiting and dyspnea; in addition, hypoperfusion of the limbs may lead to numbness, tingling, and muscle pain, or even gangrene involving the hands and feet. And finally, ergotism may lead to sustained vascular spasms, seizures, hallucinations, and even coma.

Now, methylergonovine is contraindicated in clients who have previously developed allergic reactions to ergot-derived medications.

In addition, due to its vasoconstrictive effects, methylergonovine is contraindicated in clients with cardiovascular disease, hypertension, preeclampsia, or eclampsia as well as during pregnancy, since it may stimulate contraction of the uterus and lead to decreased placental blood flow, premature labor, or even miscarriage.

Sources

  1. "Drugs and Lactation Database" National Library of Medicine (US) Bethesda (MD)
  2. "Focus on Nursing Pharmacology" LWW (2019)
  3. "Pharmacology" Elsevier Health Sciences (2014)
  4. "Mosby's 2021 Nursing Drug Reference" Mosby (2020)
  5. "Saunders Comprehensive Review for the NCLEX-RN Examination" Saunders (2016)